Fampridine for the treatment of schizophrenia

The effect of Fampridine as an adjuvant therapy on the improvement of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N163

Enrollment

Registered

2025-08-15

Start date

2025-09-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Control group: Patients treated with risperidone at a dose of 4-6 mg along with placebo. Intervention 2: Intervention group: Patients treated with risperidone at a dose of 4-6 mg along

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of schizophrenia based on DSM-5 Age between 18-60 At least 2 years have been passed since the diagnosis Treated with risperidone for at least 2 months (4-6mg)

Exclusion criteria

Exclusion criteria: Head trauma History of shock therapy during the last three months Neurosurgery Diagnosis of acute or chronic systemic disease Alcohol or drug addiction in the last 6 months Suicidal ideation Pregnancy or lactation IQ less than 70 based on the diagnosis of a psychiatrist Depressive symptoms and use of antidepressants

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 4 and 8. Method of measurement: By Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026